TrialNature communications2023

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer.

Tian-Mei Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.